Delving into the Latest Updates on gp140 Vaccine adjuvanted with MF59C.1(NIAID) with Synapse

Overview

Basic Info

Drug Type

Vaccine

Synonyms-

Target-

Action-

Mechanism

Immunostimulants

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

National Institute of Allergy & Infectious Diseases

Active Organization-

Inactive Organization-

License Organization-

Drug Highest Phase-

First Approval Date-

Regulation-

A Phase 1 Placebo-Controlled Study Extension to HVTN 073 / SAAVI 102, to Evaluate the Safety and Immunogenicity of Novartis Sub C gp140 Vaccine With MF59 Adjuvant, as a Boost Following SAAVI DNA-C2 Vaccine and SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Adult Participants in South Africa and the United States

This is an extension of the HVTN 073/SAAVI 102 study. This study will evaluate the safety and immune response to an HIV envelope protein vaccine boost in people who have previously received the SAAVI DNA-C2 and SAAVI MVA-C vaccines or placebo in the HVTN 073/SAAVI 102 study.

Start Date01 Aug 2011

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

100 Clinical Results associated with gp140 Vaccine adjuvanted with MF59C.1(NIAID)

Login to view more data

100 Translational Medicine associated with gp140 Vaccine adjuvanted with MF59C.1(NIAID)

Login to view more data

100 Patents (Medical) associated with gp140 Vaccine adjuvanted with MF59C.1(NIAID)

Login to view more data

100 Deals associated with gp140 Vaccine adjuvanted with MF59C.1(NIAID)

Login to view more data